Therapeutic Strategies Targeting Proteins That Regulate Folate and Reduced Folate Transport

REFERENCES

• Elwood PC. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 1989; 264 (25): 14893–14901.
   PubMed Web of Science ®Google Scholar
• Ratnam M, Marquardt H, Duhring L, Freisheim JH. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 1989; 28: 8249–8254.
   PubMed Web of Science ®Google Scholar
• Sadasivan E, Rothenberg SP. The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA. J Biol Chem 1989; 264: 5806–5811.
   PubMed Web of Science ®Google Scholar
• Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity and tissue specificity. Biochemistry 1994; 33: 1209–1215.
   PubMed Web of Science ®Google Scholar
• Henderson GB. Folate-binding proteins. Ann Rev Nutr 1990; 10: 319–335.
   PubMed Web of Science ®Google Scholar
• Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ. Endocytosis of GPI-linked membrane folate receptoralpha. J Cell Biol 1996; 132: 35–47.
   PubMed Web of Science ®Google Scholar
• Rothberg KG, Ying YS, Kolhouse JF, Kamen BA, Anderson RG. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin coated pit endocytic pathway. J Cell Biol 1990; 110: 637–649.
   PubMed Web of Science ®Google Scholar
• Kamen BA, Smith AK, Anderson RG. The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest 1991; 87: 1442–1449.
   PubMed Web of Science ®Google Scholar
• Anderson RG, Kamen BA, Rothberg KG, Lacey SW. Potocytosis: sequestration and transport of small molecules by calveolae. Science 1992; 255: 410–411.
   PubMed Web of Science ®Google Scholar
• Lacey S, Sanders JM, Rothberg KG, Anderson RG, Kamen BA. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol tail. J Clin Invest 1989; 84 (2): 715–720.
   PubMed Web of Science ®Google Scholar
• Ragoussis J, Senger G, Trowsdale J, Campbell IG. Genomic organization of the human folate receptor genes on chromosome 11q13. Genomics 1992; 14: 423–430.
   PubMed Web of Science ®Google Scholar
• Sadasivan E, Cedeno M, Rothenberg SP. Genomic organization of the gene and a related pseudogene for a human folate binding protein. Biochim Biophys Acta 1992; 1131: 91–94.
   PubMed Web of Science ®Google Scholar
• Ross J, Chaudhuri P, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer Res 1994; 73: 2432–2443.
   Google Scholar
• Withers DA, Harvey RC, Faust JB, Melnyk 0, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991; 11: 4846-4853.
   Google Scholar
• Roberts S, Chung K-N, Nachmanoff K, Elwood P. Tissue-specific promoters of the human folate receptor gene yield transcripts with divergent 5' leader sequences and different translational efficiencies. Biochem J 1997; 326: 439–447.
   PubMed Web of Science ®Google Scholar
• Saikawa Y, Price K, Hance K, Chen T, Elwood P. Structural and functional analysis of the human KB cell folate receptor gene P4 promotor: cooperation of three clustered Spl-binding sites with initiator region for basal promoter activ-ity. Biochemistry 1995; 34: 9951-9961.
   Google Scholar
• Wang H, Ross J, Ratnam M. Structure and regulation of a polymorhic gene encoding folate receptor type γ/γ Nucleic Acids Res 1998; 26 (9): 2132-2142.
   Google Scholar
• Antony AC. The biological chemistry of folate recep-tors. Blood 1992; 79: 2807–2820.
   PubMed Web of Science ®Google Scholar
• Shen F, Zheng X, Wang J, Ratnam M. Identification of amino acid residues that determine the different ligand specificities of folate receptors a and I. Biochemistry 1997; 36: 6157–6163.
   PubMed Web of Science ®Google Scholar
• Shen F, Wang H, Zheng X, Ratnam M. Expression lev-els of functional folate receptors a and 13 are related to the number of N-glycosylated sites. Biochem J 1997; 327: 759–764.
   PubMed Web of Science ®Google Scholar
• Roberts SJ, Petropavlovskaja M, Chung K-N, Knight CB, Elwood PC. Role of individual N-linked glycosylation sites in the function and intracellular transport of the human a folate receptor. Arch Biochem Biophys 1998; 351 (2): 227–35.
   PubMed Web of Science ®Google Scholar
• Mantovani LT, Miotti S, Menard S, et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies M0v18 and M0v19. Eur J Cancer 1994; 30A: 363–369.
   PubMed Web of Science ®Google Scholar
• Coney LR, Tomasetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR. Cloning of a tumor-associated antigen: M0v18 and M0v19 antibodies recognize a folate binding protein. Cancer Res 1991; 51: 6125-6132.
   Google Scholar
• Mezzanzanica D, Porro G, Pupa S, Regazoni M, Tagliabue E, Colnaghi MI. Characterization of human ovarian carcinoma associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987; 39 (3): 297–303.
   PubMed Web of Science ®Google Scholar
• Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci 1995; 92: 9057–9061.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Scheidegger D. The use of hybrid-hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987; 17: 105–111.
   PubMed Web of Science ®Google Scholar
• Canevari S, Mezzanzanica D, Mazzoni A, et al. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 1995; 4: 423–427.
   PubMedGoogle Scholar
• Canevari S, Miotti S, Bottero F, Valota 0, Colnaghi MI. Ovarian carcinoma therapy with monoclonal antibodies. Hybridoma 1993; 12: 510–507.
   Google Scholar
• Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawsli VR. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res 1994; 54 (9): 2448–2455.
   PubMed Web of Science ®Google Scholar
• Leamon CP, Paston I, Low PS. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem 1993; 268: 24847–24854.
   PubMed Web of Science ®Google Scholar
• Ladino CA, Charl R, Bourret LA, Kedersha NL, Goldmacher VS. Folate-maytansinoids; Target-selective drugs of low molecular weight. Int J Cancer 1997; 73: 859–864.
   PubMed Web of Science ®Google Scholar
• Sirotnak, FM. Obligate genetic expression in tumor cells of a fetal membrane property mediating “folate” trans-port. Biological significance and implications for improved therapy of human cancer. Cancer Res 1985; 45: 3992–4000.
   PubMed Web of Science ®Google Scholar
• Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28: 77–102.
   PubMed Web of Science ®Google Scholar
• Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J Biol Chem 1968; 243: 5007-5017.
   Google Scholar
• Henderson GB, Zevely EM. Anion exchange mecha-nism for transport of methotrexate in L1210 cells. Biochem Biophys Res Commun 1981; 99: 163–169.
   PubMed Web of Science ®Google Scholar
• Henderson GB, Zevely EM. Structural requirements of the anion substrates of the methotrexate transport system of L1210 cells. Arch Biochem Biophys 1983; 221: 438–446.
   PubMed Web of Science ®Google Scholar
• Henderson GB, Suresh MR, Vitols KS, Huennekens FM. Transport of folate compounds in L1210 cells: kinetic evidence that folate influx proceeds via the high affinity trans-port system for 5-methyltetrahydrofolate and methotrexate. Cancer Res 1986; 46: 1639-1643.
   Google Scholar
• Matherly LH, Czajkowski CA, Angeles SM. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res 1991; 51 (13): 3420–3426.
   PubMed Web of Science ®Google Scholar
• Freisheim JH, Price EM, Ratnam M. Folate coenzyme and antifolate transport proteins in normal and neoplastic tis-sues. Adv Enzyme Regul 1989; 29: 13–26.
   PubMedGoogle Scholar
• Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in L1210 leukemia. J Biol Chem 1968; 243: 5007-5017.
   Google Scholar
• Chello PL, Sirotnak FM, Dorick DM, Donsbach RC. Therapeutic relevance of differences in the structural specifici-ty of the transport systems for folate analogs in L1210 tumor cells and in isolate murine intestinal epithelial cells. Cancer Res 1977; 37: 4297-4303.
   Google Scholar
• Henderson GB, Zevely EM. Characterization of the multiple transport routes for methotrexate in L1210 cells using phthalate as a model anion substrate. J Membrane Biol 1985; 85: 263–268.
   PubMed Web of Science ®Google Scholar
• Williams F, Murray R, Underhill M, Flintoff W. Isolation of a hamster cDNA clone coding for a function involved in MTX uptake. J Biol Chem 1984; 269 (8): 5810–5816.
   Google Scholar
• Dixon KH, Lampher BC, Chin J, Kelley K, Cowan KH. A novel cDNA restores reduced folate carrier activity and MTX sensitivity to transport deficient cells. J Biol Chem 1994; 269 (1): 17–20.
   PubMed Web of Science ®Google Scholar
• Moscow JA, Gong M, He R, et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995; 55: 3790-3794.
   Google Scholar
• Williams F, Flintoff W. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995; 270: 2987–2992.
   PubMed Web of Science ®Google Scholar
• Brigle KE, Spinella ML, Sierra EE, Goldman ID. Organization of the murine reduced folate carrier gene and identification of variant splice forms. Biochim Biophys Acta 1997; 1353: 191–198.
   PubMed Web of Science ®Google Scholar
• Tolner B, Roy K, Sirotnak FM. Organization, structure and alternate splicing of the murine RFC-1 gene encoding a folate transporter. Gene 1997; 189: 1–7.
   PubMed Web of Science ®Google Scholar
• Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Therapeut 1985; 28: 77–102.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM. Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention. NCI Monogr 1987; 5: 27–35.
   PubMedGoogle Scholar
• Henderson GB, Strauss BP. Evidence for cAMP and cholate extrusion in C6 rat glioma cells by a common anion efflux pump. J Biol Chem 1991; 266: 1641-1645.
   Google Scholar
• Trippett T, Schlemmer S, Elisseyeff Y, et al. Defective transport as a mechanism of acquired resistance to methotrex-ate in patients with acute lymphoblastic leukemia. Blood 1992; 80 (5): 1158–1162.
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, et al. Defective trans-port is a common mechanism of acquired resistance in acute lymphoblastic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89 (3): 1013–1018.
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Mechanism of intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335: 1041–1048.
   PubMed Web of Science ®Google Scholar
• Gong M, Yess J, Connolly T, et al. Molecular mecha-nism of antifolate transport-deficiency in a methotrexate-resis-tant MOLT-3 human leukemia cell line. Blood 1997; 89 (7): 2494–2499.
   PubMed Web of Science ®Google Scholar
• Brigle K, Spinella M, Sierra E, Goldman IA. Characterisation of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 1995; 270 (39): 22974–22979.
   PubMed Web of Science ®Google Scholar
• Zhao R, Assaraf Y, Goldman ID. A reduced folate carri-er mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem 1998; 273 (14): 7873–7879.
   PubMed Web of Science ®Google Scholar
• Takimoto C, Allegra C. New antifolates in clinical development. Oncology 1995; 9 (7): 649–665.
   PubMedGoogle Scholar
• Fleisher M. Antifolate analogs: Mechanism of action, analytic methodology and clinical efficacy. Therapeut Drug Mngt 1993; 15: 521–526.
   PubMed Web of Science ®Google Scholar
• Jackman A, Farrugia D, Gibson W, et al. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1985; 31A(7-8): 1277–1282.
   Google Scholar
• Cunningham D, Zalcberg J, Rath U, et al. Tomudex (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leu-copenia. The Tomudex' Colorectal Cancer Study Group. Eur J Cancer 1995; 31A(12): 1945–1954.
   PubMed Web of Science ®Google Scholar
• Longo G, Gorlick R, Tong W, Erickan E, Bertino JR. Disparate affinities of antifolates for folypolyglutamate syn-thetase from human leukemia cells. Blood 1997; 90 (3): 1241–1245.
   PubMed Web of Science ®Google Scholar
• Jackson R, Leopold W, Hamelehle K, Fry D. Preclinical studies with trimetrexate: a review of conclusions and unan-swered questions. Sem Oncol 1988; 15 (suppl 2): 1-7.
   Google Scholar
• Balis F, Patel R, Luks E et al. Pediatric Phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987; 47: 4973–4976.
   Google Scholar
• Lacerda J, Goker E, Kheradpour A, et al. Selective treatment of SCID mice bearing methotrexate-transport-resis-tant human acute lymphoblastic leukemia tumors with trime-trexate and leucovorin protection. Blood 1995; 85 (10): 2675–2679.
   PubMed Web of Science ®Google Scholar
• Allegra C, Chabner B, Tuazon C et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia patients with acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 978–985.
   Google Scholar
• Sattler F, Frame P, Davis R, et al. Trimetrexate with leucovorin versus trimethoprin-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multi-center investigation of the AIDS Clinical Trials Group Protocol 029/0031. J Infect Dis 1994; 170 (1): 165–172.
   PubMed Web of Science ®Google Scholar